Biocon Launches Biosimilar Yesafili in US
Biocon Ltd. has announced the commercial launch of Yesafili™, a biosimilar aflibercept, in the United States. This marks a significant step in expanding global access to biosimilar treatments for ophthalmology conditions. Yesafili™ is an interchangeable biosimilar to Regeneron's Eylea® 2 mg, indicated for conditions like wet age-related macular degeneration and diabetic macular edema. The launch is expected to benefit millions of Americans and addresses a substantial market, with U.S. sales of aflibercept reaching approximately $5.89 billion in 2023. The product's approval was based on comprehensive data demonstrating its similarity to the reference product, with no clinically meaningful differences in efficacy or safety.
Key Highlights
- Biocon launched Yesafili™, a biosimilar aflibercept, in the United States.
- Yesafili™ is an interchangeable biosimilar to Regeneron's Eylea® 2 mg.
- The launch targets significant eye conditions like AMD and DME.
- The U.S. market for aflibercept was valued at $5.89 billion in 2023.
- This expands Biocon's presence in the ophthalmology sector.
Price Impact
More from BIOCON